ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.

If you purchased Unicycive securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Unicycive had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the U.S. Food and Drug Administration's ("FDA") cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate ("OLC") was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants' positive statements about Unicycive's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.